OneSource Specialty Pharma Limited announced that its Board has decided to undertake a further review concerning the Composite Scheme of Arrangement and Amalgamation involving several entities, including Steriscience and Strides Pharma Services. This review precedes the formal filing of the application with the National Company Law Tribunal (NCLT). The company received in-principle approval previously and will complete the review within the six-month window granted by the Stock Exchanges before proceeding further.
Update on Corporate Restructuring Scheme
OneSource Specialty Pharma Limited provided an update to the Stock Exchanges regarding the Composite Scheme of Arrangement and Amalgamation (Merger by Absorption). This complex scheme involves Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited, and Onesource Specialty Pharma Limited, along with their respective shareholders.
Decision Following Board Meeting
The Board of Directors met on March 06, 2026, to review the next steps following the receipt of in-principle approval for the acquisition of Steriscience facilities (Poland and Baroda) into OneSource. After comprehensive deliberation, the Board has resolved to undertake a further review before filing the necessary application with the National Company Law Tribunal (NCLT).
Timeline and Next Steps
The Company confirmed that this mandatory review process will be completed within the six-month approval window that was granted by the National Stock Exchange of India Limited and BSE Limited. OneSource Specialty Pharma Limited assured stakeholders that it will continue to keep the Stock Exchanges informed of any material developments concerning the Proposed Scheme.
Compliance Confirmation
The disclosure was authorized by Trisha A, Compliance Officer and Company Secretary (Membership Number: A47635).
Source: BSE
